Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23147922 | 0.81 | ACACB (0.40) | HRH3LIPENAMPTACACBMCHR1 | |
| SCHEMBL12367667 | 0.80 | HRH3 (0.46) | HRH3LIPENAMPTMEN1KMT2A | |
| SCHEMBL12367594 | 0.79 | LIPE (0.41) | HRH3LIPENAMPTMEN1KMT2A | |
| SCHEMBL13960219 | 0.78 | ACACB (0.46) | HRH3ACACBMCHR1 | |
| SCHEMBL18421612 | 0.77 | HRH3 (0.46) | HRH3LIPENAMPTMCHR1 | |
| SCHEMBL17221104 | 0.77 | LOX (0.47) | HRH3NAMPTACACB | |
| SCHEMBL12367595 | 0.76 | HPGD (0.43) | HRH3LIPENAMPTMEN1KMT2A | |
| SCHEMBL12367592 | 0.75 | PRMT5 (0.42) | LIPENAMPTMEN1KMT2A | |
| SCHEMBL30484266 | 0.74 | IKBKE (0.45) | HRH3NAMPTACACB | |
| SCHEMBL14842338 | 0.74 | IKBKE (0.45) | HRH3NAMPTACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | AZI2, GPR119, GID4 | HRH3 335/4885LIPE 8/4885NAMPT 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.